key: cord-0708353-i3dwbdzb
authors: Yıldız, Yılmaz; Sivri, H. Serap
title: Difficulties Associated with Enzyme Replacement Therapy for Mucopolysaccharidoses
date: 2021-11-01
journal: Turk Arch Pediatr
DOI: 10.5152/turkarchpediatr.2021.21235
sha: f035e34ee86bd8f884df61944f7a417380f4fa21
doc_id: 708353
cord_uid: i3dwbdzb

BACKGROUND: Mucopolysaccharidoses are extremely rare, progressive, often severe multisystem disorders, some of which are managed by weekly intravenous enzyme replacement therapy. This study aimed to determine the difficulties faced by the patients with mucopolysaccharidosis and their families due to enzyme replacement therapy. METHODS: A questionnaire about demographics, enzyme replacement therapy-related characteristics, and specific enzyme replacement therapy-related difficulties was conducted over the telephone with mucopolysaccharidosis patients (or their parents) followed at a referral center in Turkey, who have been on enzyme replacement therapy for ≥12 months. The responses were analyzed with chi-square, Mann–Whitney U, Kruskal–Wallis tests, Spearman's rank correlation, and binary logistic regression. RESULTS: A total of 54 patients (median age: 13 years) participated, who had been receiving enzyme replacemnt therapy for a median of 5.02 years, 83.3% of whom had mucopolysaccharidosis-IVA or -VI. About 72.2% went to school or work, 64.1% of whom missed a full day every week due to enzyme replacement therapy. About 63% missed at least 1 dose in the past 6 months, mostly due to not being able to obtain doses or having intercurrent infections. Significantly more enzyme replacement therapy doses were missed or unobtained in Central (non-Ankara) and Eastern Anatolia, but enzyme replacement therapy-related disruption to family life was more severe in families living in Ankara. CONCLUSIONS: We provide the first Turkish data about mucopolysaccharidosis patients’ subjective enzyme replacement therapy experience, which is influenced by actionable inequalities and hurdles, partially related to geographical factors. Access to the drugs can be facilitated, and the clash of enzyme replacement therapy infusions with school and work should be avoided. Multi-center studies using more objective data sources are needed.

Glycosaminoglycans are important components of the extracellular matrix. They are degraded in lysosomes by specific enzymes, the inherited deficiencies of which give rise to a group of lysosomal storage diseases called mucopolysaccharidoses (MPSs), classified as MPS types I, II, III (subtypes IIIA-D), IV (subtypes IVA-B), VI, VII, and IX, based on the affected enzyme. Mucopolysaccharidoses are extremely rare with a total incidence of 1-5 in 100 000 live births. 1 Mucopolysaccharidoses comprise a wide spectrum of severity and varying combinations of progressive multisystem involvement, with the severe forms associated with early mortality and low quality of life. Systemic manifestations include coarse facies, failure to thrive, developmental delay, intellectual disability, neurodegeneration, myelopathy, serous otitis media, hearing loss, corneal opacity, obstructive sleep apnea, restrictive airway disease, valvulopathy, cardiomyopathy, hepatosplenomegaly, joint stiffness and/or laxity, and skeletal dysplasia. 2 Symptomatic management by multidisciplinary experts is required for all types of MPS, but specific treatment targeting the underlying enzyme deficiency is only available as intravenous enzyme replacement therapy (ERT) in certain MPS types (weekly in MPS-I, II, IVA, and VI, biweekly in MPS-VII) and as hematopoietic stem cell transplantation (HSCT) in selected MPS-I patients. 2, 3 While ERT improves or stabilizes cardiac dysfunction, obstructive sleep apnea, organomegaly, and endurance, it has little effect on growth, skeletal dysplasia, neurodegeneration, keratopathy, and pulmonary disease, which still account for significant morbidity and mortality. 3 Enzyme replacement therapy is clearly a difficult treatment, but the personal difficulties of ERT is drastically understudied in comparison to the impact of the disease itself. In addition to the already high disease burden, patients and their families have to endure the difficulties brought on by ERT, including frequent travel to an infusion center, repeated intravenous cannula insertions (complicated by rough skin), absenteeism from school or work, and ERT-related adverse events. Furthermore, access to the ERT drug is not straightforward. At the time this study was performed, the only specific MPS treatment available in standard pharmacies and reimbursed by the Social Security Agency (SSA) in Turkey was indicated for MPS-I. Enzymerelated therapy for MPS-II, IVA, and VI were also reimbursed by the SSA, but the drugs were not available in pharmacies and had to be imported and dispensed for each patient via the Turkish Pharmacists' Association (TPA). Additionally, physicians had to apply to the Ministry of Health for permission to use the drug for each MPS-IVA patient and renew approval at intervals specified by the Ministry. The SSA began reimbursing ERT for MPS-VII (vestronidase) only recently in 2021. 4 Our study aimed to document the difficulties and associated factors related to ERT among MPS patients followed at a single center.

This was a cross-sectional questionnaire study conducted over the telephone in August-November 2018. It was approved by the Hacettepe University Ethics Board for Non-interventional Clinical Studies ( . The participants consisted of MPS patients followed at our department who have been receiving ERT for at least 12 months at the time of the interview and provided informed consent as approved by the ethics board. Patients who received experimental treatments (e.g. gene therapy), were prescribed ERT with a non-standard regimen (e.g. tapering down after HSCT), or were obtaining the ERT drug via non-standard procedures (e.g. compassionate use program) were excluded.

Eligible patients were contacted over the phone, and the responding patient or parent was surveyed with a questionnaire including their demographic and medical characteristics, ERT history, missed or delayed doses of ERT in the past 6 months, and their problems about acquiring the drugs and accessing medical care to receive ERT. A "missed dose" was defined as not receiving the dose for that week, and a "delayed dose" was defined as receiving it within the week but later than the scheduled day. The level of disruption caused by ERT on the patient's and the family's daily life was assessed by a 5-point Likert scale (none, minor, neutral/unsure, moderate, or severe, corresponding to 1-5 points in order), reflecting the subjective view of the respondent. 5

Statistical analyses were performed with Statistical Package for the Social Sciences (SPSS) version 22.0 (IBM SPSS Corp.; Armonk, NY, USA). The qualitative data were expressed as numbers and percentages. Central tendencies were reported as mean ± SD or median as appropriate. Normality of the distributions was assessed with the Kolmogorov-Smirnov (n ≥ 50) and Shapiro-Wilk (n < 50) tests (all non-normal). Numerical data from independent groups were compared by the Mann-Whitney U or the Kruskal-Wallis tests (for 2 or more groups, respectively). Post hoc pairwise comparisons after the Kruskal-Wallis tests used the Bonferroni correction for adjustment of the P value. Associations between 2 numerical variables were analyzed with Spearman's rank correlation and those between 2 categorical variables with chi-square test or Fisher's exact test, as dictated by the test conditions. P < .05 was accepted to be statistically significant. Variables independently associated with missed or delayed doses (0-1 dose vs. 2 or more doses) and with disruption to daily life (1-2 vs. 4-5 points on Likert scale) were analyzed with binary logistic regression using forward stepwise likelihood ratio, including variables found to be significantly associated in previous tests or variables of clinical interest (see "Results" section for details). Regression models were rejected if they failed to provide good fit for the actual data distribution (P value of the Hosmer-Lemeshow chi-square less than .05). 6

Fifty-four patients participated in the study, whose demographics are presented in Table 1 Enzyme replacement therapy-related characteristics are also summarized in Table 1 . The mean age at initiation of ERT was 7.87 ± 6.50 years (median: 6.21, range: 0.40-26.41), and the mean ERT duration was 6.08 ± 3.10 years (median: 5.02, range: 1.00-12.40). All participants were prescribed weekly ERT. None had a central venous catheter, all requiring peripheral venous cannula placement for each infusion. In most patients (92.6%), the cannula could be placed in 1 or 2 attempts (mean: 1.46 ± 0.77 attempts, median: 1, range: 1-5). In total, 16 patients (29.6%) had a history of ERT-related adverse events, 12 of whom had non-life-threatening infusion reactions. Four patients reported anaphylaxis to ERT, but they did not experience clinically relevant morbidity or mortality and were able to continue ERT after desensitization.

Responses regarding the logistics of ERT and acquisition of the drugs are presented in Table 2 The difficulties related to acquisition of the drugs and disruptions to the weekly infusions were diverse ( Table 2) . A total of 63.0% reported missing at least 1 dose in the past 6 months, mostly due to not being able to obtain adequate doses (35.3%), followed by intercurrent acute infections (29.4%). Failure to obtain the drug was predominantly related to the TPA not acquiring and sending the drug in time (82.4%). A total of 35.2% reported delaying at least 1 dose in the past 6 months, mostly due to unavailability of hospital beds. Self-reported levels of disruption to daily living of the patient and of the family caused by ERT were found to be balanced across the 5-point Likert scale (mean: 3.02 ± 1.60, median: 3 points; and 3.11 ± 1.53, median: 3 points, respectively, Table 3 ).

Correlations among the numerical and ordinal data revealed mostly statistically insignificant or significant but weak correlations (P > .05 or P < .05 but Spearman's |ρ| < 0.40, respectively). Statistically significant moderate or strong correlations (|ρ|>0.60 and P < .05) existed only between the levels of disruption to daily lives of the patients and that of the families (ρ = +0.729, P < .001) and between the numbers of missed and unobtained ERT doses (ρ = +0.686, P < .001). The number of missed doses in the past 6 months did not differ significantly by gender, the type of MPS, intellectual disability, the administrative status of the place of residence, the infusion center, going to school or work, disruption to the hospital companion's regular job, or a history of ERT-related adverse effects (P > .05) but differed significantly in relation to the geographical region of residence (Table 4) . Similarly, the number of unobtained drug doses also differed significantly by the geographical region (Table 4) but not by gender, the type of MPS, intellectual disability, the infusion center, going to school or work, or a history of adverse effects (P > .05). The number of unobtained doses also differed significantly according to the administrative status of the place of residence (P = .042), which arose from the difference between provincial centers and small settlements (village, town) (0.48 ± 0.96 vs. 1.67 ± 0.58 doses in the past 6 months, respectively, adjusted P = .044).

Parameters associated with the levels of ERT-related disruption to the patient's life and to the family's life were investigated. While the reported disruption to the patient's life and the family life were strongly and positively correlated with each other (see above), they did not exhibit moderate or strong significant correlations with other numerical or ordinal variables. There were no significant differences in the levels of disruption to the patient's or the family's life in relation to MPS type, intellectual disability, gender, administrative status of the place of residence, patient's attendance to school or work, or the presence of adverse effects (P > .05). The level of disruption to family life differed significantly with regard to the geographical region (Table 4 ) and the infusion center (P = .010). The level of disruption to family life was significantly higher in those receiving ERT at our center (4.60 ± 0.52 points, n = 10) than those receiving ERT at state hospitals (2.96 ± 1.52 points, n = 23, adjusted P = .049) and at other university hospitals (2.40 ± 1.40 points, n = 15, adjusted P = .005). The level of disruption to the patient's own life did not differ significantly with regard to the geographical region (P = .166) or the infusion center (P = .231).

In binary logistic regression analysis, a model satisfying the predetermined requirements could not be constructed using the level of disruption to family life as the dependent variable. The models constructed for the level of disruption to the patient's life and for the numbers of missed and unobtained doses in the past 6 months are summarized in Table 5 . The only statistically significant model with acceptable sensitivity, specificity, and accuracy was the one revealing the number of unobtained doses as the most important variable independently associated with the number of missed doses, but it could explain only 39.9% of the variance in the number of missed doses (Table 5 ).

The efficacy of ERT in MPS has been widely studied, including recent reports from Turkey. 7-10 Local information on demographic and clinical characteristics is also available. 11 The number of missed doses is significantly higher in Central Anatolia (not Ankara) and Eastern Anatolia than the Black Sea Region (P = .004 and P = .012, respectively). Although the number of unobtained doses is higher in Central Anatolia (not Ankara) and Eastern Anatolia, pairwise comparisons do not show significant differences among regions after the Bonferroni correction. Similarly, while the level of disruption to family life related to ERT was higher in Ankara, the statistical significance of the differences did not persist after the adjustment of the P value by the Bonferroni correction. The other parameters depicted in the only a single study by Zengin et al. 13 has addressed the difficulties of living with MPS in Turkey, based on interviews with parents of 10 children with MPS. Although their study was mainly concerned with the burden of the disease, themes coinciding with our study also emerged, including school attendance and difficulties in social life. 13 A German study on 10 MPS-VI patients with a Turkish background also addressed the difficulties and coping strategies but mainly in relation to the disease rather than the treatment. 14 To the best of our knowledge, ours is the first study from Turkey to investigate the difficulties related specifically to ERT in MPS. In a patient population mostly participating in social life (school or work), dominated by intellectually normal MPS-IVA and MPS-VI patients who had been on ERT for 1-12 years, we have demonstrated that compliance to ERT is fairly good (a mean of 1.35 ± 1.43 missed weekly doses in the past 6 months), but ERT experience is influenced by actionable inequalities and hurdles, which are partially related to sociodemographic factors.

A total of 64.1% of MPS patients who go to school or work miss an entire day every week due to ERT. High absenteeism from school or work has also been reported by Solano et al. 15 in MPS-IVA and VI patients from Latin America, but mostly due to disease burden and progression, and its relation to ERT was largely unexplored. In already disadvantaged patients with sensory, motor, and/or learning disabilities, 20% absence from school or work solely due to ERT should be avoided. A potential solution could be scheduling ERT after-hours or on weekends, which would require allocation of health care workforce. Since most patients do not have problems with intravenous access and adverse events are rare and manageable, home treatment is a viable option and can increase compliance. [16] [17] [18] Our data suggest that this might not be a priority because all patients receive ERT close to their home, and compliance is already high. However, it should be noted that this study was performed before the coronavirus disease 2019 pandemic, which has caused treatment interruptions and increased disease burden in our patients due to limited access to infusion centers. 19 In fact, the need to transfer ERT services to home has emerged in different parts of the world, 20,21 and could be considered in Turkey, as well.

Multiple statistical tools point to unobtained doses as the most significant cause of missing ERT, and this is largely related to delayed delivery from the TPA. As outlined above, access to the ERT drug is a multi-step process which might be hard for families to navigate. Licensing the drugs and making them available in local pharmacies could greatly ease and hasten the process of obtaining the ERT drugs. Patients living in Central Anatolia (in provinces other than Ankara) and Eastern Anatolia, especially in small settlements, have a disadvantage in obtaining drug doses and continuing ERT without interruption. The study by Solano et al. 15 has shown that ERT interruption due to temporary unavailability of the drug is similarly common in Latin America, but this did not differ significantly among urban and rural areas. It is possible that the apparent influence of geographical factors is confounded by economic, social, and cultural factors not addressed in our study and is probably only a part of well-known regional health disparities, 22 requiring broader socioeconomic and public health interventions for improvement.

It is interesting that in the questionnaire respondents reported a bidirectionally skewed subjective disruption to daily life of the patient and the family, with similar numbers of respondents stating that there is little to no disruption versus moderate to severe disruption (Table 3) , again associated with the geographical region. It has been reported that cultural factors, including religious background, which were not explored in our questionnaire, can influence how Turkish families deal with MPS. 13, 14 In fact, faith is a common coping mechanism for caregivers of chronic patients, 23 and its influence may apply to the burden of the treatment as well as that of the disease. This study suggests that in contrast to missing ERT doses, more disruption to family life is associated with receiving ERT infusions at our center. However, since most patients from Ankara receive infusions at our center, it is difficult to differentiate whether receiving ERT at our center or living in Ankara is actually causative of the disruption to family life. Although the reasons for missing or delaying a dose are not significantly different between patients going to different infusion centers, a post hoc look at the data shows that 4 out of 6 patients who missed a dose and 4 out of 9 patients who postponed a dose in the past 6 months due to unavailability of hospital beds were those coming to our hospital for their weekly ERT, which necessitates a self-criticism and reevaluation of the capacity and functioning of our infusion unit. Even though missed or delayed doses were not significantly associated with disruption to family life, it can be argued that problems with scheduling a sick child's regular weekly treatment in a metropolis like Ankara can easily cause strain on family life. In fact, although caregivers in rural areas may have worse socioeconomic indices, they report similar emotional stress and better health than their urban counterparts, 24 which may be related to the numerous difficulties of living in a large city. Dedicated, flexible, patient-and family-friendly infusion centers in larger cities may alleviate the families' burden related to ERT.

Our study has several limitations. Perhaps most importantly, since the data were gathered not from objective health records, but from questionnaire answers provided by the patients or their parents, the study is prone to recall bias and social desirability bias. The questionnaire was designed by the researchers and was not a validated tool. Although 54 is a substantial number of participants for such a rare disease group and reflects valuable experience from a single center, it is still too small a number to empower advanced statistical methods. We did not gather information on literacy, economic status, or quality of life, which could have contributed to more comprehensive data interpretation. On the other hand, quality of life is influenced greatly by the disease itself and could have steered away from the burden related to ERT, the actual focus of the study.

Despite its limitations, this study provides the first data about the ERT experience of Turkish MPS patients. While the geographic health disparities are concerning, there is also room for improvement in facilitating access to the drugs and circumventing the clash of ERT infusions with school and work. Multi-center studies using more objective sources and taking into account more data may overcome some of the limitations of this study.

Ethical Committee Approval: Ethics committee approval was received from the Hacettepe University Ethics Board for Non-interventional Clinical Studies (approval number: .

Informed Consent: Informed consent was obtained from all participants who participated in this study.

Peer Review: Externally peer-reviewed. 

Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities

Update in the mucopolysaccharidoses

Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations

A technique for the measurement of attitudes

Applied Logistic Regression

The effectiveness of enzyme replacement therapy on cardiac findings in patients with mucopolysaccharidosis

Morquio A syndrome and effect of enzyme replacement therapy in different age groups of Turkish patients: a case series

Genotypic-phenotypic features and enzyme replacement therapy outcome in patients with mucopolysaccharidosis VI from Turkey

Mukopolisakkaridoz tip VI'lı çocuklarda kardiyovasküler bulgular ve enzim replasman tedavisinin etkisi

Maroteaux-Lamy Sendromu) Tanılı Hastalarda Klinik deneyim

Evaluation of demographic and clinical characteristics of patients with mucopolysaccharidosis

Difficulties experienced by Turkish parents and their coping strategies: children with mucopolysaccharidosis

Illness perception and clinical treatment experiences in patients with M. Maroteaux-Lamy (mucopolysaccharidosis type VI) and a Turkish migration background in Germany

Montaño HPQ. Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American countries

Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively

Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses

Home infusion with Elosulfase alpha (Vimizim R ) in a UK Paediatric setting

Invisible burden of COVID-19: enzyme replacement therapy disruptions

Challenges in chronic genetic disorders: lessons from the COVID-19 pandemic

Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience

Türkiye Nüfus ve Sağlık Araştırması. Ankara: Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü, T.C. Cumhurbaşkanlığı Strateji ve Bütçe Başkanlığı, TÜBITAK

A study on caregiver burden: stressors, challenges, and possible solutions

Rural-urban differences in unpaid caregivers of adults. Rural Remote Health

The authors would like to thank the patients and their families for participating in this study and the health care staff who contributed to the diagnosis and management of these patients.

The authors have no conflicts of interest to declare.

The authors declared that this study has received no financial support.